22 JANUARY 2025 NORTHERN 2 VCT PLC DIRECTOR/PDMR DEALINGS Northern 2 VCT PLC (“the Company”) has been notified that in respect of the allotment of new ordinary shares pursuant to the Company’s Dividend Investment Scheme, the following PDMR acquired ordinary shares of 5 pence each in the Company.PDMR Date acquired No. of shares acquired Purchase priceper share (£) Total currentshareholdingCecilia McAnulty 22 January 2025 2,340 0.5550 164,608These notifications are made in accordance with the Market Abuse Regulations.1 Details of the person discharging managerial responsibilities / person closely associateda) Name Cecilia McAnulty   2 Reason for the notificationa) Position / status Director (PDMR)b) Initial notification / amendment Initial notification3   Details of the issuer, emission allowance market participant,...

This announcement contains Alm. Brand Group’s profit guidance for 2025 and information about the realised financial results for 2024. The interim report for Q4 2024 will be released as announced on 5 February 2025. Alm. Brand Group is set to continue the positive performance in 2025 and expects to report an insurance service result of DKK 1.5-1.7 billion excluding run-off gains or losses. The profit guidance includes synergies in an amount of DKK 600 million. The expected increase relative to the result realised in 2024 is driven by improved profitability in both Personal Lines and Commercial Lines due to the implementation of profitability-enhancing initiatives. The expense ratio is expected to be about 17% in 2025, and the combined ratio excluding run-offs is expected to be about 85.5-87.5. The target for 2025 of generating an insurance...

Quadient strengthens its financial position through a USD100 million US Private Placement from MetLife Paris, January 22, 2025 Quadient S.A. (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, today announces that it has signed a new USD100 million US Private Placement (USPP) with MetLife Investment Management (“MIM”), reinforcing its financial position. This new USPP of USD 100 million senior notes has a 7-year average maturity and comes with an additional shelf facility allowing the issue of senior notes for a maximum aggregate principal amount of USD50 million. Since the beginning of the financial year 2024 and including this transaction, Quadient has successfully raised the equivalent of €330 million through various financial instruments including a Schuldschein, term loans and...

(2025-01-22) Kitron has received an order with a value of NOK 300 million from Kongsberg Defence & Aerospace (KONGSBERG). The order covers electronics for the Naval Strike Missile (NSM) and extends a similar contract awarded in June 2024. Deliveries under the new order are set to commence in 2026, with production taking place at Kitron’s facilities in Arendal, Norway. “We are very pleased to announce this order, which confirms Kitron’s position as a robust and reliable Kitron and industrial partner for Kongsberg,” says Heine Østby, Managing Director, Kitron Norway. “The long-standing collaboration between our two companies continues to strengthen, and Kitron’s ongoing investment in a new production facility in Arendal is well aligned with this increase in orders. This ensures secure and efficient deliveries for this critically important...

22 January 2025: Borregaard ASA (”Borregaard”, OSE ticker: BRG) Presentation of Q4 2024 results Borregaard will report fourth quarter 2024 results on Wednesday 29 January 2025 at 07:00 CET. A stock exchange announcement will be made. A press release, the quarterly report and a presentation will be made available on https://www.borregaard.com/investors/. A presentation of the fourth quarter 2024 results will also be held at 08:30 CET at Carnegie Investment Bank Norway, Fjordalléen 16, Oslo. We welcome you to attend physically – if so, please register by e-mail to ca@carnegie.no. The presentation can be followed live on web-TV at https://www.borregaard.com/investors/. It will be possible to ask questions via the web. All presentations will be held in English. For more information about Borregaard ASA, please visit https://www.borregaard.com/. Contact:Lotte...

Oslo, 22 January 2025 Reference is made to the stock exchange announcement made by Belships ASA (“Belships” or the “Company“) on 21 January 2025, regarding the approval of the offer document (the “Offer Document“) by Blue Northern BLK Ltd. (“Blue Northern” or the “Offeror“) for the recommended voluntary cash tender offer (the “Offer“) to acquire all issued and outstanding shares of Belships (the “Shares“) against a cash consideration of NOK 20.50 (the “Offer Price“) per Share, and commencement of the offer period today, 22 January 2025. Reference is further made to the stock exchange announcement made by the Company on 19 December 2024, pursuant to which it was disclosed that the members of the Company’s board of directors (the “Board“)...

More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to accurate, easy-to-use diagnostics for all patients in decentralized settings like urgent care centers, retail clinics, and community health venues. The tests use highly sensitive, gold-standard PCR technology, providing results in 20 minutes to allow healthcare providers to confidently diagnose and determine appropriate treatment in the same visit.Basel, 22 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas® liat sexually transmitted infection (STI) multiplex...

Nokia Corporation Stock Exchange Release22 January 2025 at 08:00 EET Patrik Hammarén appointed as President of Nokia TechnologiesPatrik Hammarén appointed as President of Nokia Technologies and member of the Nokia Group Leadership TeamEspoo, Finland – Nokia today announced the appointment of Patrik Hammarén as President of Nokia Technologies and member of the Nokia Group Leadership Team, effective 22 January 2025. Nokia Technologies is responsible for managing and monetizing Nokia’s intellectual property, including the company’s industry leading patent portfolio. The business group licenses Nokia’s innovation and contributions to global technology standards to other companies. Hammarén joined Nokia in 2007 and has been acting President of Nokia Technologies since October 2024. Prior to this role, Patrik held several senior positions...

Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myelomaApproval is based on positive results from the IMROZ phase 3 study, demonstrating Sarclisa in combination with standard-of-care treatment significantly improved PFS, compared to the standard of care alone in TI NDMM Represents third indication in the EU, including two for the treatment of adult patients with R/R MM, and one in NDMMParis, January 22, 2025. Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed...